JP2020524689A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524689A5
JP2020524689A5 JP2019570806A JP2019570806A JP2020524689A5 JP 2020524689 A5 JP2020524689 A5 JP 2020524689A5 JP 2019570806 A JP2019570806 A JP 2019570806A JP 2019570806 A JP2019570806 A JP 2019570806A JP 2020524689 A5 JP2020524689 A5 JP 2020524689A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
plasminogen
composition according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524689A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/000655 external-priority patent/WO2018234861A1/en
Publication of JP2020524689A publication Critical patent/JP2020524689A/ja
Publication of JP2020524689A5 publication Critical patent/JP2020524689A5/ja
Pending legal-status Critical Current

Links

JP2019570806A 2017-06-23 2018-06-22 Pai−1過剰発現に関連する状態のプラスミノーゲン処置 Pending JP2020524689A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23
US62/523,901 2017-06-23
PCT/IB2018/000655 WO2018234861A1 (en) 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression

Publications (2)

Publication Number Publication Date
JP2020524689A JP2020524689A (ja) 2020-08-20
JP2020524689A5 true JP2020524689A5 (enExample) 2021-07-29

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570806A Pending JP2020524689A (ja) 2017-06-23 2018-06-22 Pai−1過剰発現に関連する状態のプラスミノーゲン処置

Country Status (21)

Country Link
US (1) US11826404B2 (enExample)
EP (1) EP3641888B1 (enExample)
JP (1) JP2020524689A (enExample)
KR (1) KR20200019217A (enExample)
CN (1) CN110831668B (enExample)
AU (1) AU2018287316B2 (enExample)
BR (1) BR112019027229A2 (enExample)
CA (1) CA3068153A1 (enExample)
CL (1) CL2019003789A1 (enExample)
DK (1) DK3641888T3 (enExample)
ES (1) ES2965937T3 (enExample)
FI (1) FI3641888T3 (enExample)
IL (1) IL271470B2 (enExample)
MX (1) MX2019015741A (enExample)
MY (1) MY203136A (enExample)
NZ (1) NZ760921A (enExample)
RU (1) RU2020100080A (enExample)
SG (1) SG11201912813SA (enExample)
TW (1) TWI868051B (enExample)
WO (1) WO2018234861A1 (enExample)
ZA (1) ZA202000280B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
WO2018107690A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法
CA3167202A1 (en) * 2020-02-06 2021-08-12 Jinan Li Method and drug for preventing and treating multiple sclerosis
TW202144000A (zh) * 2020-03-24 2021-12-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療帕金森氏症的方法和藥物
KR20220156934A (ko) * 2020-03-24 2022-11-28 탈렌젠 인터내셔널 리미티드 잘못 접힌 단백질 및 이의 응집체 분해의 촉진 방법 및 약물
TWI868333B (zh) * 2020-03-24 2025-01-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療阿茲海默症的方法和藥物
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
CN101563100B (zh) * 2006-08-28 2013-08-07 李季男 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标
CA2662083C (en) * 2006-08-28 2016-09-20 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
SG10201710013RA (en) * 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
JP7168990B2 (ja) * 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CN110167582A (zh) * 2016-12-15 2019-08-23 泰伦基国际有限公司 一种预防和治疗药物性肾损伤的方法
CN110191718A (zh) * 2016-12-15 2019-08-30 泰伦基国际有限公司 一种预防和治疗组织器官纤维化的方法

Similar Documents

Publication Publication Date Title
JP2020524689A5 (enExample)
BR112015009504A2 (pt) inibidores de rock
JP2013516482A5 (enExample)
JP2011225596A5 (enExample)
JP2013520405A5 (enExample)
JP2016511267A5 (enExample)
JP2015528471A5 (enExample)
RU2020100080A (ru) Лечение состояний, связанных с сверхэкспрессией pai-1, с помощью плазминогена
JP2017506624A5 (enExample)
JP2011528333A5 (enExample)
JP2017105861A5 (enExample)
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
JP2017105859A5 (enExample)
JP2014139255A5 (enExample)
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
JP2015502389A5 (enExample)
JP2014508758A5 (enExample)
CA2519679A1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
JP2015522077A5 (enExample)
RU2014112324A (ru) Применение органического соединения для лечения синдрома нунан
JP2012525358A5 (enExample)
JP2016505050A5 (enExample)
JP2019507786A5 (enExample)
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
JP2010519192A5 (enExample)